In breast cancer, METTL3 accelerates miR-221-3p precursor maturation, induces MDR1 and BCRP expression via the miR-221-3p/HIPK2/Che-1 axis, then promotes adriamycin resistance in cancer cells [113]. Here, METTL3 is linked to cancer.